Literature DB >> 25150325

Hip dysplasia in the skeletally mature patient.

Rachel Y Goldstein, Ian David Kaye, James Slover, David Feldman.   

Abstract

Abnormal hip development causes one-quarter to one-half of all hip disease. Dysplastic hips typically share characteristic anatomic abnormalities. The dysplastic acetabulum is typically shallow, lateralized, and anteverted with insufficient coverage anteriorly, superiorly, and laterally. The dysplastic proximal femur has a small femoral head with excessive femoral neck anteversion and a short neck with an increased neck shaft angle. These characteristic changes result in intraarticular pathology leading to hip arthritis. A variety of treatment options exist based on the degree of dysplasia and the amount of concomitant hip arthritis. Treatment options include hip arthroscopy, acetabular or femoral osteotomies, hip arthrodesis, and total hip arthroplasty.

Entities:  

Mesh:

Year:  2014        PMID: 25150325

Source DB:  PubMed          Journal:  Bull Hosp Jt Dis (2013)        ISSN: 2328-4633


  4 in total

Review 1.  The Use of Biologics for Hip Preservation.

Authors:  Toufic R Jildeh; Muhammad J Abbas; Patrick Buckley; Kelechi R Okoroha
Journal:  Curr Rev Musculoskelet Med       Date:  2021-01-23

Review 2.  The role of arthroscopy in the dysplastic hip-a systematic review of the intra-articular findings, and the outcomes utilizing hip arthroscopic surgery.

Authors:  Suenghwan Jo; Sang Hong Lee; Sung Il Wang; Bjorn Smith; John O'Donnell
Journal:  J Hip Preserv Surg       Date:  2016-01-09

Review 3.  Abnormal Femoral Anteversion Is Associated With the Development of Hip Osteoarthritis: A Systematic Review and Meta-Analysis.

Authors:  Emily A Parker; Alex M Meyer; Momin Nasir; Michael C Willey; Timothy S Brown; Robert W Westermann
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-09-02

Review 4.  Current Concepts in Hip Preservation Surgery: Part I.

Authors:  Kelly L Adler; P Christopher Cook; Yi-Meng Yen; Brian D Giordano
Journal:  Sports Health       Date:  2015-05-18       Impact factor: 3.843

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.